Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 5/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | TLR4 | O00206 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933160 | 1.00 | ALDH1A1 (0.54) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL1441840 | 0.90 | ALDH1A1 (0.45) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL9950395 | 0.85 | ALDH1A1 (0.50) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL9950324 | 0.85 | ALDH1A1 (0.50) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL25935100 | 0.81 | ALDH1A1 (0.57) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL15221619 | 0.81 | ALDH1A1 (0.65) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL9470730 | 0.81 | ALDH1A1 (0.65) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL15221598 | 0.81 | ALDH1A1 (0.65) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL13580104 | 0.80 | ALDH1A1 (0.62) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL761181 | 0.80 | ALDH1A1 (0.76) | ALDH1A1GAACTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2504339-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2011064211-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | CYP1B1, CYP11B2, CCNI | ALDH1A1 385/4885GAA 1035/4885CTSL 3832/4885 |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | ALDH1A1 477/4885GAA 891/4885CTSL 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.